Inpatient use of metformin and acarbose is associated with reduced mortality of COVID‐19 patients with type 2 diabetes mellitus

Mostrar otras versiones (1)

AIMS: Type 2 diabetes mellitus (T2DM) is a strong risk factor for complications of coronavirus disease 2019 (COVID‐19). The effect of T2DM medications on COVID‐19 outcomes remains unclear. In a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID‐19 in Wuhan, we have p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jinghong, Wei, Qi, McCowen, Karen C., Xiong, Wei, Liu, Jiao, Jiang, Wenlijun, Thomas, Robert L., Hepokoski, Mark, He, Ming, Shyy, John Y. J., Malhotra, Atul, Xiong, Nian, Li, Willis X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646242/
https://www.ncbi.nlm.nih.gov/pubmed/34585841
http://dx.doi.org/10.1002/edm2.301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646242/
https://www.ncbi.nlm.nih.gov/pubmed/34585841
http://dx.doi.org/10.1002/edm2.301

Ejemplares similares